Business Context and Reporting Period
This Form 8-K is filed by Aethlon Medical, Inc. (Nasdaq: AEMD) on January 7, 2025. The report addresses the status of the Company's listing on The Nasdaq Capital Market regarding compliance with the Minimum Bid Price Requirement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory listing status rather than financial performance.
Material Changes
The primary material event is the receipt of an extension from Nasdaq to regain compliance with the Minimum Bid Price Requirement. Previously, the Company had 180 days (until December 24, 2024) to comply after its stock closed below $1.00 per share for 31 consecutive trading days. On January 7, 2025, Nasdaq granted an additional 180-day extension.
Guidance, Outlook, and Risks
- Compliance Deadline: The Company now has until June 23, 2025, to regain compliance.
- Compliance Criteria: To regain compliance, the bid price of the common stock must close at $1.00 per share or more for a minimum of 10 consecutive trading days prior to June 23, 2025.
- Delisting Risk: If the Company fails to regain compliance by the new deadline, Nasdaq will notify the Company of delisting. The Company may appeal this determination, but there is no assurance of success.
- Management Intent: The Company intends to monitor the closing bid price and may consider implementing available options to regain compliance.
- Immediate Impact: The extension notice has no immediate effect on the current listing status or SEC reporting requirements.
Investor Verification Checklist
- Verify the current closing bid price of AEMD stock relative to the $1.00 threshold.
- Monitor the stock price for 10 consecutive trading days to assess progress toward compliance.
- Review future filings for any announcements regarding reverse stock splits or other corporate actions intended to raise the share price.
- Confirm the final compliance deadline of June 23, 2025.